Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mepolizumab→

Mepolizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
196078-29-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Interleukin-5 Antagonist
Mechanism of action
Interleukin-5 Antagonists [MoA]
Indications / reported uses
  • Asthma
  • acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5
  • acute bronchospasm [see Warnings and Precautions ( 5
  • adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
  • adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mepolizumab Environmental Risk Assessment (ERA) (the Mepolizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.